Business Wire: July 27, 2017 – HAYWARD, CA, U.S.A. – Aradigm Corporation (NASDAQ: ARDM) (the “company”) today announced it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Linhaliq™ for the treatment of non-cystic fibrosis bronchiectasis (NCFBE)…
